BEIJING (Reuters) – China’s Kintor Pharmaceutical Ltd said data from a Phase III clinical trial for its potential COVID-19 treatment proxalutamide in non-hospitalised patients did not meet statistical criteria in the interim analysis.
Kintor said in a filing on Monday that it will seek authorities’ consent to amend clinical protocol and continue to enroll patients of higher risk.
(Reporting by Beijing newsroom; Editing by Kirsten Donovan)
